Diabetic Neuropathies
Conditions
Keywords
Type II diabetic mellitus, Diabetic neuropathy, Electromyography
Brief summary
The goal of this clinical trial is to learn the differences severity level of diabetic neuropathy based on electromyelography in type II diabetic patient with and without comorbidities. The main questions of this study: 1. What is the electromyography result in type II diabetic patient who: has no comorbidities, with hypertension, with hypertension and dyslipidemia? 2. Is there any differences in electromyography result in type II diabetic patient who: has no comorbidities, with hypertension, with hypertension and dyslipidemia? 3. Is there any association between distal latency with nerve conduction velocity in type II diabetic patient with and without comorbidities? 4. Is there any association between distal latency with amplitude in type II diabetic patient with and without comorbidities? 5. Is there any differences on diabetic neuropathy severity based on age, height, and A1C levels in type II diabetic patient with and without comorbidities? Researchers will collect information based on hospital registry as secondary data of in type II diabetic patient with and without comorbidities. The data consist of demographic data, clinical presentation, laboratory, and electromyography were collected from hospital registry by reviewing medical record. Then, the data was analyzed by using IBM SPSS Statistics v26.
Interventions
DIAGNOSTIC_TESTElectromyography
All of groups will have assessment of electromyography result
Sponsors
Universitas Diponegoro
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Inclusion criteria
* Diabetic neuropathy patient who classified as distal symmetrical polyneuropathy * Diabetic neuropathy patient who has no comorbidities * Diabetic neuropathy patient who has hypertension * Diabetic neuropathy patient who has hypertension and dyslipidemia
Exclusion criteria
* Diabetic neuropathy patient with history of chemotherapy * Diabetic neuropathy patient with history of hernia nucleus pulposus * Diabetic neuropathy patient with history of CKD stage V or on routine dyalisis * Missing data on medical record
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Distal Latency | Electromyography examination was done approximately 1 year after clinical onset of neuropathy appear | Distal latency defined as time between stimuli until deflection of Compound Muscle Action Potentials (CMAP) from baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Nerve Conduction Velocity | Electromyography examination was done approximately 1 year after clinical onset of neuropathy appear | Nerve Conduction Velocity defined as the measurement of axon conduction velocity by dividing space of nerve conduction with time needed |
| Amplitude | Electromyography examination was done approximately 1 year after clinical onset of neuropathy appear | Amplitude define as the height of first negative deflection of Compound Muscle Action Potentials (CMAP) from baseline |
Countries
Indonesia
Outcome results
None listed